BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34631715)

  • 1. The RNA N6-Methyladenosine Methyltransferase METTL3 Promotes the Progression of Kidney Cancer via N6-Methyladenosine-Dependent Translational Enhancement of ABCD1.
    Shi Y; Dou Y; Zhang J; Qi J; Xin Z; Zhang M; Xiao Y; Ci W
    Front Cell Dev Biol; 2021; 9():737498. PubMed ID: 34631715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma.
    Zhu D; Liu Y; Chen J; Wang Q; Li Y; Zhu Y; Feng J; Jiang J
    J Transl Med; 2022 Jul; 20(1):298. PubMed ID: 35794583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
    Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression.
    Xiang S; Liang X; Yin S; Liu J; Xiang Z
    Am J Transl Res; 2020; 12(5):1789-1806. PubMed ID: 32509177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
    Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
    Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
    Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
    J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism.
    Xie W; Ma LL; Xu YQ; Wang BH; Li SM
    Biochem Biophys Res Commun; 2019 Oct; 518(1):120-126. PubMed ID: 31405565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation.
    Yuan Y; Du Y; Wang L; Liu X
    J Cancer; 2020; 11(12):3588-3595. PubMed ID: 32284755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.
    Zhang Z; Fu J; Zhang Y; Qin X; Wang Y; Xing C
    BMC Gastroenterol; 2023 Jun; 23(1):217. PubMed ID: 37344779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway.
    Yang DD; Chen ZH; Yu K; Lu JH; Wu QN; Wang Y; Ju HQ; Xu RH; Liu ZX; Zeng ZL
    Front Oncol; 2020; 10():115. PubMed ID: 32175271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
    Wang H; Xu B; Shi J
    Gene; 2020 Jan; 722():144076. PubMed ID: 31454538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL3-mediated m
    Han H; Yang C; Zhang S; Cheng M; Guo S; Zhu Y; Ma J; Liang Y; Wang L; Zheng S; Wang Z; Chen D; Jiang YZ; Lin S
    Mol Ther Nucleic Acids; 2021 Dec; 26():333-346. PubMed ID: 34513313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
    Ouyang D; Hong T; Fu M; Li Y; Zeng L; Chen Q; He H; Wen Y; Cheng Y; Zhou M; Zou Q; Yi W
    Breast Cancer Res; 2023 Feb; 25(1):19. PubMed ID: 36765397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
    Xu H; Wang H; Zhao W; Fu S; Li Y; Ni W; Xin Y; Li W; Yang C; Bai Y; Zhan M; Lu L
    Theranostics; 2020; 10(13):5671-5686. PubMed ID: 32483411
    [No Abstract]   [Full Text] [Related]  

  • 17. m
    Xu L; Li Q; Wang Y; Wang L; Guo Y; Yang R; Zhao N; Ge N; Wang Y; Guo C
    Am J Cancer Res; 2021; 11(11):5282-5298. PubMed ID: 34873461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. METTL3-Mediated N6-Methyladenosine Modification Is Involved in the Dysregulation of NRIP1 Expression in Down Syndrome.
    Shi W; Yang F; Dai R; Sun Y; Chu Y; Liao S; Hao B
    Front Cell Dev Biol; 2021; 9():621374. PubMed ID: 33869171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblasts promote migration and invasion of non-small cell lung cancer cells via METTL3-mediated RAC3 m
    Chen M; Zhang Q; Zheng S; Guo X; Cao L; Ren Y; Qian Y; Wang M; Wu X; Xu K
    Int J Biol Sci; 2023; 19(5):1616-1632. PubMed ID: 37056933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
    Ma Z; Li Q; Liu P; Dong W; Zuo Y
    Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.